Condition: Acute Lymphoblastic Leukemia (ALL) in Complete Remission · Acute Myeloid Leukemia (AML) in Remission · Sponsor: King Faisal Specialist Hospital & Research Center
This randomized clinical trial will evaluate two approaches of GvHD prophylaxis; the standard of care GVHD prophylaxis regimen (methotrexate/calcineurin inhibitors) and post-transplant cyclophosphamide with calcineurin inhibitors for their efficacy as a new GVHD prophylaxis strategy.
This description comes directly from the study's public registry record.
Riad O El Fakih, MD · + 966114647272 · relfakih1@kfshrc.edu.sa
Always discuss trial participation with your own doctor first.
| King Faisal Specialist Hospital & Research Center | Riyadh, Saudi Arabia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04314219